🕵️ Evommune, Inc. ($EVMN)
SEC insider & ownership activity, last 12 months · CIK 2044725 · every row links its SEC filing
Over the last 12 months insiders sold $2.3M against $70.2M of open-market buying. Verduyn-Van Weegen Felice Isabel bought $25.0M in discretionary trades (Nov). LSP 7 Cooperatieve U.A. trimmed 15.7% → 14.7%; RA Capital Management, L.P. trimmed 11.0% → 9.7%. No red-flag 8-Ks in the window.
Monthly net open-market insider flow, last 12 months (up = net buying)
Insider flow
6 buyers, $70.2M (7 lots) · 6 sellers, $2.3M (9 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| Verduyn-Van Weegen Felice Isabel | 1 | $25.0M | 0 | – | Nov 7, 2025 |
| LSP 7 Cooperatieve U.A. | 1 | $25.0M | 0 | – | Nov 7, 2025 |
| RA Capital Management, L.P. | 2 | $20.0M | 0 | – | Nov 7, 2025 |
| Luis C. Pena | 0 | – | 2 | $551K | Jun 22, 2026 |
| Janice Drew | 0 | – | 1 | $453K | Jun 22, 2026 |
| Kyle Carver | 1 | $13K | 1 | $415K | Jul 8, 2026 |
| Patel Jeegar Pravinkumar | 0 | – | 2 | $413K | Jun 22, 2026 |
| Gregory S. Moss | 0 | – | 1 | $325K | May 28, 2026 |
| Arthur S. Kirsch | 1 | $133K | 0 | – | Jul 7, 2026 |
| David E. Cohen | 0 | – | 2 | $123K | Jun 2, 2026 |
| Hopfner Robert Lorne | 1 | $17K | 0 | – | Dec 19, 2025 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| LSP 7 Management B.V. | 14.7% | 13D | Feb 12, 2026 | filing ↗ | |
| LSP 7 Cooperatieve U.A. | 14.7% | 13D | Feb 12, 2026 | filing ↗ | |
| NAN FUNG Group Holdings Limited | 10.9% | 13G | Feb 13, 2026 | filing ↗ | |
| NF Investment Holdings Limited | 10.7% | 13G | Feb 13, 2026 | filing ↗ | |
| NAN FUNG Life Sciences Holdings Limited | 10.7% | 13G | Feb 13, 2026 | filing ↗ | |
| RA Capital Management, L.P. | 9.7% | 13D | Feb 12, 2026 | filing ↗ | |
| Peter Kolchinsky | 9.7% | 13D | Feb 12, 2026 | filing ↗ | |
| Rajeev Shah | 9.7% | 13D | Feb 12, 2026 | filing ↗ | |
| RA Capital Healthcare Fund, L.P. | 7.5% | 13D | Feb 12, 2026 | filing ↗ | |
| Pivotal Life Sciences Holdings Limited | 6.1% | 13G | Feb 13, 2026 | filing ↗ | |
| Pivotal Partners Ltd | 6.1% | 13G | Feb 13, 2026 | filing ↗ | |
| Andera Partners | 6.0% | 13G | Nov 17, 2025 | filing ↗ | |
| Biodiscovery 6 FPCI | 6.0% | 13G | Nov 17, 2025 | filing ↗ | |
| Stephane Bergez | 6.0% | 13G | Nov 17, 2025 | filing ↗ | |
| Francois Xavier Mauron | 6.0% | 13G | Nov 17, 2025 | filing ↗ | |
| POINT72 Asset Management, L.P. | 5.3% | 13G | Jul 16, 2026 | filing ↗ | |
| POINT72 Capital Advisors, Inc. | 5.3% | 13G | Jul 16, 2026 | filing ↗ | |
| Steven A. Cohen | 5.3% | 13G | Jul 16, 2026 | filing ↗ | |
| Pivotal Bioventure Partners Fund I U.G.P. Ltd. | 5.2% | 13G | Feb 13, 2026 | filing ↗ | |
| Pivotal Bioventure Partners Fund I G.P., L.P. | 5.2% | 13G | Feb 13, 2026 | filing ↗ | |
| Pivotal Bioventure Partners Fund I, L.P. | 5.2% | 13G | Feb 13, 2026 | filing ↗ |
Planned insider sales (Form 144)
| Seller | Planned | Approx. sale date | |
|---|---|---|---|
| Janice Drew | $427K | Jun 22, 2026 | filing ↗ |
| David Cohen | $205K | Jun 2, 2026 | filing ↗ |
| Luis Pena | $563K | Jun 1, 2026 | filing ↗ |
| Jeegar Patel | $422K | Jun 1, 2026 | filing ↗ |
| Gregory Moss | $332K | May 28, 2026 | filing ↗ |
| Kyle Carver | $599K | May 28, 2026 | filing ↗ |
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Reg FD disclosure (7.01) | Jun 29, 2026 | filing ↗ |
| Other events (8.01) | Jun 29, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 29, 2026 | filing ↗ |
| Shareholder vote (5.07) | Jun 2, 2026 | filing ↗ |
| Earnings (2.02) | May 7, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | May 7, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Apr 13, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Apr 13, 2026 | filing ↗ |
| Earnings (2.02) | Mar 5, 2026 | filing ↗ |
| Material agreement (1.01) | Feb 12, 2026 | filing ↗ |
| Unregistered equity sale (3.02) | Feb 12, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Feb 12, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Feb 12, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Feb 10, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Feb 10, 2026 | filing ↗ |
| Earnings (2.02) | Dec 11, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Dec 11, 2025 | filing ↗ |
| Charter/bylaw changes (5.03) | Nov 7, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 7, 2025 | filing ↗ |